This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

DATE OF LIVE ACTIVITY

Wednesday, October 26, 2022 from 7:30 – 8:30pm ET

TARGET AUDIENCE

The educational design of this activity addresses the needs of ophthalmologists who diagnose and treat patients with neovascular retinal diseases, including nAMD, DME, and/or RVO, and other clinicians involved in the management of patients with neovascular retinal diseases.

STATEMENT OF NEED/PROGRAM OVERVIEW

While the prevalence of neovascular eye diseases is increasing, anti-vascular endothelial growth factor (VEGF) agents, which have repeatedly been shown to preserve or improve visual acuity, have dramatically improved the outlook for patients, their families, and their caregivers. However, early anti-VEGF agents approved for retinal vascular disorders – e.g., neovascular (wet) age-related macular degeneration, diabetic macular edema/diabetic retinopathy, and retinal vein occlusion – are limited by the need for frequent intravitreal injections and the potential for adverse events.

Join a panel of expert ophthalmologists to review the efficacy and safety of emerging options for neovascular retinal diseases, including new anti-angiogenesis agents and novel intravitreal delivery systems. Panelists will discuss the time commitments and logistical challenges faced by patients who require intravitreal injections. Experts will then analyze the most current evidence on new options to manage retinal disorders and explore their ability to reduce the treatment burden imposed on patients and caregivers and improve patients’ quality of life.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Recognize the burden and concerns that retinal vascular diseases (AMD, DME/DR, and RVO), as well as their traditional treatments with anti-VEGF agents, pose for patients and their caregivers
• Summarize current data on the efficacy and safety of new and emerging treatment options and delivery system for retinal vascular disorders, including dual-acting bispecific monoclonal antibodies that block VEGF and inhibit angiopoietin 2
• Discuss the place of new agents and delivery devices in the care of patients with vascular retinal diseases

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURES OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Dante J. Pieramici, MD Director California Retina Research Foundation Partner, California Retina Consultants Member, Retina Consultants of America	Consultant: Adverum, Clearside, Genentech, Ophthea Perceive, Regeneron, Regenx Bio, and Unity Grant/Research Support: Adverum, Apellis, Clearside, Genentech, Greybug, Kodiac, NGM, Ocular, Ocular Therapeutic, Oculis, Ophthea, Oxurion, Perceive, Regeneron, Regenx Bio, Stealth, Unity, and Valo
Carl Regillo, MD Director, Wills Eye Retina Service Professor of Ophthalmology Thomas Jefferson University	Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Clearside, Eyepoint, Genentech, Graybug, Iveric, Kodiac, Lineage, Merck, NGM, Novartis, Ocugen, RegenXBio, Stealth, Thea, and Zeiss Grant/Research Support: Adverum, Allergan, Annexon, Apellis, Astellis, Eyepoint, Genentech, Graybug, Gyroscope, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Opthea, Regeneron, and RegenXBio Stockholder: Iveric and Ocugen

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Eve Wilson, PhD, FACEHP	Nothing to disclose
Stephanie Puccio	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.